Navigation Links
PharmAthene Announces Proposed Common Stock Offering
Date:10/28/2010

ANNAPOLIS, Md., Oct. 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners, LLC. is acting as sole underwriter for the offering.

The shares are being offered by PharmAthene pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission ("SEC") on February 13, 2009. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Roth Capital Partners, LLC Syndicate Department,  24 Corporate Plaza, Newport Beach, CA 92660, at 800-678-9147 and Rothecm@roth.com. Before you invest, you should read the prospectus and prospectus supplement in that registration statement and other documents PharmAthene has filed or will file with the SEC for more complete information about PharmAthene and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About PharmAthene, Inc.

PharmAthene was formed to meet
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Announces $3.9 Million Registered Direct Offering
2. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
3. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
4. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
5. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
6. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
7. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
8. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
9. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
10. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
11. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research ... the "Genotyping Market by Technology, Application & by ... their offering. The global genotyping market is ... Billion in 2015, at a CAGR of 22.3% during ... Market growth will be attributed to the availability of ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 “Stem Cell Therapy ... more mainstream, and it is used often as an adjunct ... general practitioners are not yet aware or comfortable enough with ... therapy is most often reserved for the last resort cases ... pet can barely lift a paw to get around. It ...
(Date:6/2/2015)... , June 2, 2015  RXi ... biotechnology company focused on discovering and developing ... dermatology and ophthalmology, today announced that Dr. ... will present at the 23 rd ... world congress will include in-depth presentations by ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Through rare ... technology, Yancy Corporation is enabling World Scientists ... material and biological sample, displaying the full nature (position, ... between atoms. , Jeff Porter, Co-Founder of the Yancy ... just that – rare. They come once in a ...
Breaking Biology Technology:Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2
... Carolina, July 26, 2011 ... research organisation (CRO) with a trusted process for ... Swiss-based global biopharmaceutical group with a focus on ... strategic partnership. Under the terms of the agreement, ...
... CLINTON TOWNSHIP, Mich., July 25, 2011 Robert Ettinger, the ... died on Saturday, July 23, at home in Clinton Township, ... movement advocates storage at very low temperatures after death in ... cure of aging and disease. Mr. Ettinger ...
... 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... completed the randomized portion of its Phase 3 clinical ... for the treatment of moderate to severe chronic pain, ... "We are very pleased to have brought ...
Cached Biology Technology:INC Research and Debiopharm Group(TM) Announce Strategic Partnership 2INC Research and Debiopharm Group(TM) Announce Strategic Partnership 3Founder of Cryonics Movement Dies, is Frozen at Cryonics Institute 2BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 2BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 3
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... R. LeDuc will join more than 70 of the ... Keck Futures Initiative on Complexity at the Beckman Conference ... discuss the topic of complexity in areas spanning everything ... sustainable future. , "This is a great opportunity ...
... LANSING, Mich. Cholesterol crystals released in the bloodstream ... linings much further away from the site of the ... George Abela, a physician in Michigan State University,s ... of Medicine,s cardiology section, is leading innovative research into ...
... more induced abortions have a reduced risk of pre-eclampsia by ... physical activity during pregnancy protects against pre-eclampsia, compared to previous ... Norwegian Institute of Public Health (NIPH) that use data from ... The new results from MoBa were presented on Friday 7th ...
Cached Biology News:Carnegie Mellon's Philip LeDuc participates in think tank forums 2Previous abortions and exercise: Do they affect pregnancy? 2Previous abortions and exercise: Do they affect pregnancy? 3
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Affinity Purified Anti-Human NP-1...
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
HES-1 [Hairy 1], Available Summer 2003...
Biology Products: